Adoptive immunotherapy with allogeneic Epstein–Barr virus (EBV)‐specific cytotoxic T‐lymphocytes for recurrent, EBV‐positive Hodgkin disease

BACKGROUND It has been shown that adoptive immunotherapy with Epstein–Barr virus (EBV)‐specific cytotoxic T‐lymphocytes (CTL) is effective for the treatment of EBV‐induced lymphoproliferative disease in stem cell transplantation recipients and organ transplantation recipients. The role of EBV CTL in...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer 2004-05, Vol.100 (9), p.1892-1901
Hauptverfasser:	Lucas, Kenneth G., Salzman, Donna, Garcia, Alejandro, Sun, Qi
Format:	Artikel
Sprache:	eng
Schlagworte:	Biological and medical sciences Cohort Studies Epstein-Barr virus Epstein-Barr Virus Infections - complications Epstein-Barr Virus Infections - diagnosis Epstein-Barr Virus Infections - therapy Epstein–Barr virus (EBV) Female Hematologic and hematopoietic diseases Hodgkin disease (HD) Hodgkin Disease - complications Hodgkin Disease - drug therapy Hodgkin Disease - virology Humans immunotherapy Immunotherapy, Adoptive - methods Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis lymphoma Male Medical sciences Pilot Projects Prognosis Prospective Studies Recurrence Risk Assessment Severity of Illness Index Survival Rate T-Lymphocytes, Cytotoxic - transplantation Transplantation, Homologous Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!